Guest guest Posted January 25, 2006 Report Share Posted January 25, 2006 Treatment and evaluation of CLL: a complicated affair Neil E. Kay MAYO CLINIC In this issue, Eichhorst and colleagues show in a large randomized phase 3 clinical trial that combination therapy using fludarabine and cyclophosphamide is superior to fludarabine alone for younger previously untreated CLL patients. In addition, they found a reduced level of clinical responses when imaging was considered as part of restaging compared with responses defined by recommended NCI standards. These are heady times for chronic lymphocytic leukemia (CLL) caregivers, with significant progress in both prognosis evaluation and treatment options. The course of this complicated heterogeneous disease may be very difficult to predict for a given patient even with the novel prognostic tools now available.1 In addition, we now have an increasing array of choices for use, including single or combination use of various purine nucleosides, alkylating agents, and monoclonal antibodies Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.